JP2016509222A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509222A5
JP2016509222A5 JP2015556042A JP2015556042A JP2016509222A5 JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5
Authority
JP
Japan
Prior art keywords
acid
subject
biomarkers
level
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509222A (ja
JP6404834B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011759 external-priority patent/WO2014120449A1/en
Publication of JP2016509222A publication Critical patent/JP2016509222A/ja
Publication of JP2016509222A5 publication Critical patent/JP2016509222A5/ja
Application granted granted Critical
Publication of JP6404834B2 publication Critical patent/JP6404834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556042A 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 Active JP6404834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361758924P 2013-01-31 2013-01-31
US61/758,924 2013-01-31
PCT/US2014/011759 WO2014120449A1 (en) 2013-01-31 2014-01-16 Biomarkers related to insulin resistance progression and methods using the same

Publications (3)

Publication Number Publication Date
JP2016509222A JP2016509222A (ja) 2016-03-24
JP2016509222A5 true JP2016509222A5 (https=) 2017-02-09
JP6404834B2 JP6404834B2 (ja) 2018-10-17

Family

ID=51262841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556042A Active JP6404834B2 (ja) 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法

Country Status (5)

Country Link
US (2) US9910047B2 (https=)
EP (2) EP3321686B1 (https=)
JP (1) JP6404834B2 (https=)
ES (2) ES2987582T3 (https=)
WO (1) WO2014120449A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907525A1 (en) * 2013-03-28 2014-10-02 Nestec S.A. Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
US10060932B2 (en) * 2013-07-09 2018-08-28 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
JP6609282B2 (ja) * 2016-05-17 2019-11-20 国立大学法人大阪大学 糖尿病を判定するための血液試料の分析方法及びシステム
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
ES3004083T3 (en) * 2016-12-19 2025-03-11 Metabolon Inc Mass spectrometry assay method for detection and quantitation of kidney function metabolites
WO2018150077A1 (en) * 2017-02-16 2018-08-23 Afekta Technologies Oy Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases
CN118883748A (zh) * 2017-03-31 2024-11-01 奎斯特诊断投资有限公司 用于定量胰岛素和c-肽的方法
EP3401683A1 (en) * 2017-05-10 2018-11-14 Eberhard Karls Universität Tübingen Medizinische Fakultät Diagnosing metabolic disease by the use of a biomarker
CN111727038B (zh) * 2018-01-17 2025-05-13 南安普顿大学 肌肉减少症和nad缺乏的风险预测及分级方法
EP3857232A1 (en) * 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
WO2021222309A1 (en) * 2020-04-27 2021-11-04 Ixcela, Inc. Detection and modification of gut microbial population
CN112149311B (zh) * 2020-10-12 2021-10-26 北京中恒利华石油技术研究所 一种基于数量规约的非线性多元统计回归测井曲线预测方法
CN112843036A (zh) * 2021-01-29 2021-05-28 中国药科大学 β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用
CN116087487B (zh) * 2021-11-08 2025-06-03 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
EP4504961A1 (en) * 2022-04-07 2025-02-12 Need4Health B.V. Method for determining insulin dosage
JP7736971B2 (ja) * 2022-10-18 2025-09-10 株式会社オルトメディコ 糖尿病境界域者のスクリーニング方法
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2005094200A2 (en) 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP2339346B1 (en) * 2006-03-24 2014-09-03 Metanomics GmbH Methods for predicting diabetes type II
MX2010000414A (es) 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
WO2010005982A2 (en) 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
WO2010007106A1 (en) * 2008-07-15 2010-01-21 Metanomics Health Gmbh Means and methods diagnosing gastric bypass and conditions related thereto
US20120122981A1 (en) 2009-03-31 2012-05-17 Yun Fu Hu Biomarkers Related to Insulin Resistance and Methods using the Same
US8367418B2 (en) * 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US9217747B2 (en) * 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
US20150065366A1 (en) * 2011-11-11 2015-03-05 Metabolon, Inc. Biomarkers for Bladder Cancer and Methods Using the Same
CA2853202A1 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same

Similar Documents

Publication Publication Date Title
JP2016509222A5 (https=)
Vaes et al. Changes in physical activity and all-cause mortality in COPD
Kim et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea
Nygaard et al. Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training
Wood et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains
Henderson et al. How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children?
ES2669620T3 (es) Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan
Durrer et al. Differential impact of acute high-intensity exercise on circulating endothelial microparticles and insulin resistance between overweight/obese males and females
Roumen et al. Predictors of lifestyle intervention outcome and dropout: the SLIM study
Ramon et al. Hospital admissions and exercise capacity decline in patients with COPD
Macinnis et al. Methods to estimate V˙ O2max upon acute hypoxia exposure
Pietrobelli et al. Adipose tissue and metabolic effects: new insight into measurements
García-Hermoso et al. Fatness mediates the influence of muscular fitness on metabolic syndrome in Colombian collegiate students
Teixeira et al. Skeletal maturity and oxygen uptake in youth soccer controlling for concurrent size descriptors
Zagatto et al. Relationship between anaerobic capacity estimated using a single effort and 30-s tethered running outcomes
Aerenhouts et al. Estimating body composition in adolescent sprint athletes: Comparison of different methods in a 3 years longitudinal design
Van Manen et al. Scalp hair cortisol and testosterone levels in patients with sarcoidosis
Scott et al. The intensity of a resistance exercise session can be quantified by the work rate of exercise
Ning et al. Serum creatinine-and cystatin C-based indices are associated with the risk of subsequent sarcopenia: evidence from the China health and retirement longitudinal study
Golec et al. Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study
Espinosa-Flores et al. A scoping review of the methods used in patients with liver cirrhosis to assess body composition and their nutritional findings
Tee et al. Effects of exercise modality combined with moderate hypoxia on blood glucose regulation in adults with overweight
Boghosian et al. Risk factors for developing Perthes disease: a comprehensive national analysis spanning 2 decades
Robertson et al. A glossary for social-to-biological research
Zuniga et al. The effect of different exercise protocols and regression-based algorithms on the assessment of the anaerobic threshold